In vivo imaging and quantification of CXCR4 expression in lung cancer subtypes using 68Ga-Pentixafor PET/CT and Flow cytometry analysis: A single center and First Asian Experience

Conclusions: This study concludes that 68Ga Pentixafor is a promising future PET molecule for imaging CXCR4 over expression reported in lung cancer and many other human malignancies. This novel PET tracer has the potential of becoming a powerful tool for monitoring therapy response to CXCR4 inhibitors and also for the development of emerging alpha/beta targeted therapies in advanced stage lung carcinoma. $$graphic_078CAB3A-2C78-49E0-8A2E-0F11F0BF0518$$

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Watts, A., Singh, B., Dhanota, N., Vohra, M., Kumar, R., Singh, H., Bal, A., Kapoor, R., Arora, S., Wester, H., Radotra, B., Mittal, B., Behera, D. Tags: Lung Cancer I: Molecular Biomarkers and Molecular Imaging Signatures Source Type: research